Financial reports
10-K
2023 FY
Annual report
1 Apr 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
ARS
2022 FY
Annual report to shareholders
19 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
25 Mar 22
Current reports
8-K
Entry into a Material Definitive Agreement
3 Apr 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
1 Apr 24
8-K
Unregistered Sales of Equity Securities
21 Mar 24
8-K
Other Events
8 Feb 24
8-K
Other Events
25 Jan 24
8-K
Departure of Directors or Certain Officers
18 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
8 Jan 24
8-K
Titan Pharmaceuticals Announces Reverse Stock Split and Ratio
28 Dec 23
8-K
Other Events
15 Nov 23
8-K
Titan Pharmaceuticals Announces Appointment of Dato’ Seow Gim Shen and Brynner Chiam to the Company’s Board of Directors
16 Oct 23
Registration and prospectus
RW
Registration withdrawal request
26 Apr 24
S-8
Registration of securities for employees
24 Oct 23
S-1
IPO registration
23 Jun 23
424B2
Prospectus for primary offering
5 Apr 22
S-1/A
IPO registration (amended)
4 Apr 22
S-1/A
IPO registration (amended)
28 Mar 22
S-1
IPO registration
10 Feb 22
D
$7.02M in options / securities to be acquired, sold $1.52M, 1 investor
7 Feb 22
424B5
Prospectus supplement for primary offering
3 Feb 22
424B2
Prospectus for primary offering
8 Feb 21
Proxies
DEF 14A
Definitive proxy
28 Nov 23
PRE 14A
Preliminary proxy
17 Nov 23
DEFA14A
Additional proxy soliciting materials
19 May 23
DEF 14A
Definitive proxy
19 May 23
DEFN14A
Definitive proxy statement filed by non-management
25 Jul 22
PRRN14A
Revised preliminary proxy statement filed by non-management
22 Jul 22
PREN14A
Preliminary proxy statement filed by non-management
14 Jul 22
DFAN14A
Additional proxy materials by non-management
11 Jul 22
DEFA14A
Additional proxy soliciting materials
29 Dec 21
DEFA14A
Additional proxy soliciting materials
22 Dec 21
Other
EFFECT
Notice of effectiveness
5 Apr 22
CORRESP
Correspondence with SEC
31 Mar 22
CORRESP
Correspondence with SEC
31 Mar 22
UPLOAD
Letter from SEC
16 Feb 22
EFFECT
Notice of effectiveness
8 Feb 21
CORRESP
Correspondence with SEC
4 Feb 21
UPLOAD
Letter from SEC
2 Feb 21
EFFECT
Notice of effectiveness
16 Dec 20
UPLOAD
Letter from SEC
15 Dec 20
CORRESP
Correspondence with SEC
14 Dec 20
Ownership